Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Immun Inflamm Dis. 2021 Jun;9(2):583-594. doi: 10.1002/iid3.420. Epub 2021 Apr 10.
Immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and autoimmune neutropenia (AIN) are disorders characterized by immune-mediated destruction of hematopoietic cell lineages. A link between pediatric immune cytopenias and inborn errors of immunity (IEI) was established in particular in the combined and chronic forms.
Aim of this study is to provide clinical-immunological parameters to hematologists useful for a prompt identification of children with immune cytopenias deserving a deeper immunological and genetic evaluation.
We retrospectively collected 47 pediatric patients with at least one hematological disorder among which persistent/chronic ITP, AIHA, and AIN, aged 0-18 years at onset of immune cytopenias and/or immune-dysregulation. The cohort was divided into two groups (IEI+ and IEI-), based on the presence/absence of underlying IEI diagnosis. IEI+ group, formed by 19/47 individuals, included: common variable immune deficiency (CVID; 9/19), autoimmune lymphoproliferative syndrome (ALPS; 4/19), DiGeorge syndrome (1/19), and unclassified IEI (5/19).
IEI prevalence among patients with ITP, AIHA, AIN, and Evans Syndrome was respectively of 42%, 64%, 36%, and 62%. In IEI+ group the extended immunophenotyping identified the presence of statistically significant (p < .05) specific characteristics, namely T/B lymphopenia, decrease in naїve T-cells%, switched memory B-cells%, plasmablasts%, and/or immunoglobulins, increase in effector/central memory T-cells% and CD21low B-cells%. Except for DiGeorge and three ALPS patients, only 2/9 CVID patients had a molecular diagnosis for IEI: one carrying the pathogenic variant CR2:c.826delT, the likely pathogenic variant PRF1:c.272C> and the compound heterozygous TNFRSF13B variants p.Ser144Ter (pathogenic) and p.Cys193Arg (variant of uncertain significance), the other one carrying the likely pathogenic monoallelic variant TNFRSF13B:p.Ile87Asn.
The synergy between hematologists and immunologists can improve and fasten diagnosis and management of patients with immune cytopenias through a wide focused clinical/immunophenotypical characterization, which identifies children worthy of IEI-related molecular analysis, favouring a genetic IEI diagnosis and potentially unveiling new targeted-gene variants responsible for IEI phenotype.
免疫性血小板减少症(ITP)、自身免疫性溶血性贫血(AIHA)和自身免疫性中性粒细胞减少症(AIN)是由造血细胞谱系免疫介导破坏引起的疾病。儿科免疫性血细胞减少症与先天性免疫缺陷(IEI)之间的联系,特别是在联合和慢性形式中已经建立。
本研究旨在为血液学家提供临床免疫学参数,以便快速识别需要更深入免疫和遗传评估的免疫性血细胞减少症患儿。
我们回顾性收集了 47 名儿科患者的资料,这些患者在发病时年龄为 0-18 岁,至少有一种血液学疾病,包括持续性/慢性 ITP、AIHA 和 AIN,以及免疫失调。根据是否存在潜在的 IEI 诊断,将该队列分为两组(IEI+和 IEI-)。IEI+组由 19 名患者组成,包括:普通可变免疫缺陷(CVID;9/19)、自身免疫性淋巴增生综合征(ALPS;4/19)、DiGeorge 综合征(1/19)和未分类的 IEI(5/19)。
ITP、AIHA、AIN 和 Evans 综合征患者的 IEI 患病率分别为 42%、64%、36%和 62%。在 IEI+组中,扩展免疫表型分析确定了存在统计学显著(p<0.05)的特异性特征,即 T/B 淋巴细胞减少、幼稚 T 细胞%下降、记忆 B 细胞%转换、浆母细胞%和/或免疫球蛋白增加、效应/中央记忆 T 细胞%和 CD21 低 B 细胞%增加。除了 DiGeorge 和 3 名 ALPS 患者外,只有 2 名 CVID 患者的 IEI 有分子诊断:一名携带致病性变异 CR2:c.826delT,可能致病性变异 PRF1:c.272C>和复合杂合 TNFRSF13B 变异 p.Ser144Ter(致病性)和 p.Cys193Arg(意义不明的变异),另一名携带可能致病性单等位基因 TNFRSF13B:p.Ile87Asn 变异。
血液学家和免疫学家之间的协同作用可以通过广泛的针对性临床/免疫表型特征来改善和加快免疫性血细胞减少症患者的诊断和治疗,从而确定值得进行 IEI 相关分子分析的儿童,有利于 IEI 的遗传诊断,并可能揭示导致 IEI 表型的新的靶向基因变异。